Profusa, Inc. to acquire G3 Vision Labs Inc.

Profusa, Inc. has agreed to acquire G3 Vision Labs Inc. in a strategic acquisition within the healthcare sector. The transaction involves the exchange of shares as the primary form of consideration. Both the acquiring entity and the target company are based in the United States. The deal was officially announced on 31 July 2026. No financial details regarding the valuation of the transaction have been disclosed to the public. The current status of the agreement is recorded as a firm intention by the parties involved. This indicates that both sides are committed to proceeding with the acquisition, although final completion has not yet been achieved. The structure of the deal relies on equity rather than cash, which may have implications for the shareholders of both companies once the integration process begins.

The transaction remains pending further developments. It is subject to regulatory approval and other customary closing conditions. No specific timeline for completion has been provided in the available information. The focus remains on the strategic alignment between the two healthcare entities. Investors and market observers will await further announcements regarding the finalisation of the share exchange. The absence of a disclosed deal value suggests that the parties may prefer to keep financial terms confidential during the initial stages of the merger process. This approach is not uncommon in strategic acquisitions where valuation metrics are complex or sensitive. The outcome will determine the future operational structure of G3 Vision Labs Inc. under the Profusa, Inc. umbrella.